Masteron is the trade name for the anabolic steroid Drostanolone. It is an injectable oil-based anabolic steroid derived from Dihydrotestosterone (DHT). The parent hormone makes Masteron a member of the family of anabolic steroids and DHT derivatives. In fact, all varieties of anabolic steroids in one form or another are modifications of the three main hormones that are naturally present in the body: Testosterone, DHT and Nandrolone. The precursor hormone or parent hormone of Masteron is Dihydrotestosterone. The DHT family also includes: Anavar, Winstrol, Anadrol, Primobolan and others. Masteron is not included in the list of strong anabolic steroids, but it is not among the weak ones either. Its anabolic power is considered moderate (anabolic index 62-130), and androgenic – rather low (25-40). In this, it differs significantly from Testosterone, which is used as a control measuring indicator when comparing the anabolic indices of steroids. Testosterone is the number one hormone, natural and original steroid has an androgenic and anabolic index of 100.
Description and history of the drug
The Masteron formula (under the brand name Drostanolone) was first introduced and published in 1959. Its origin is quite interesting. This substance was synthesized and produced by Syntex, a well-known development of other popular anabolic steroids such as Anadrol and Methyldrol (known as Superdrol). It wasn’t until 10 years after the formula was introduced that Masteron finally hit the market. Lilly and Syntex have worked together to develop and market various pharmaceuticals. The organizations agreed that they would jointly invest resources and bear the costs of research and development, while one of the companies determined through negotiations will receive the rights to the drug. As a result, the rights to Masteron went to Lilly. She introduced the drug to the American market under the brand name Drolban. Syntex, instead of following the distribution of Masteron on international marketplaces, also sold this anabolic steroid.
Masteron has been approved by the FDA (Food and Drug Administration) as a treatment for patients with breast cancer. The drug is well suited for women. Since, in comparison with Testosterone, Masteron has a lower androgenic index, the frequency of virilization symptoms is lower than that of other anabolic steroids. The prescriptions and instructions for the drug explain that the likelihood of developing virilization with Masteron is much less than when taking similar doses of Testosterone Propionate. The problem was that women were initially prescribed Masteron at a dosage of 300 mg per week, which apparently turned out to be too high a dose. This is also confirmed by the fact that in most cases, when taking the drug at the indicated dose, patients experienced virilization. Women who took Masteron long-term courses faced a similar problem.
Masteron’s popularity among bodybuilders and athletes began in the 1970s and increased in the 1980s. In the medical field, Masteron began to lose ground as other, more effective treatments for breast cancer were developed. Over time, pharmaceutical companies have withdrawn the drug from production. In America, Drolban ceased to be sold in the 1980s, then two other drugs under the Masteron brand were officially withdrawn from sale. Although Masteron remains on the list of approved drugs today, it is not manufactured and therefore not sold in the US (or any Western) markets.
Chemical characteristics of Masteron
Masteron is the brand name for Drostanolone. As mentioned earlier, the drug is a modified form of DHT (Dihydrotestosterone) and belongs to the family of DHT derivatives and their analogues. The methyl group of Masteron is located at the 2nd carbon atom (known as carbon-alpha). This modification is responsible for the anabolic strength, which is much lower than that of Testosterone. The addition of a methyl group enhances Masteron’s anabolic power, making it resistant to being metabolized to inactive metabolites by the enzyme 3-hydroxysteroid dehydrogenase. This enzyme is present in high amounts in muscle tissue and is the enzyme that serves to metabolize any DHT into two non-anabolic inactive metabolites: 3-alpha-androstanediol and 3-beta-androstanediol. For this reason, DHT does not work as an anabolic agent in muscle tissue. Many chemists and biologists agree that the absence of the enzyme 3-hydroxysteroid dehydrogenase in muscle would make DHT a very potent anabolic steroid.
In any case, the addition of Masteron’s methyl group to the 2-alpha carbon effectively offsets its ability to be metabolized by the enzyme 3-hydroxysteroid dehydrogenase.
There are two different varieties of Masteron: Drostanolone Propionate and Drostanolone Enanthate. The Propionate variant is more popular than Enanthate. We will explain the reason using the example of Drostanolone Propionate. “Propionate” is propanoic acid. In interaction with Masteron, she creates a bond, called in chemistry ester (ester bond). In the chemical structure of Drostanolone (Masteron), propanoic acid is linked to a 17-beta-hydroxyl group. The addition of this ester changes the half-life and release of the hormone, making it longer than the esterified hormone. Enzymes of the body destroy the bond between the ether and the hormone at different rates – the longer and larger the ester, the longer it takes to break the bond. As a result, the ester is eliminated, leaving pure Masteron (or any other pre-esterified anabolic steroid) that is now free to perform its function in the body. This characteristic feature of enzymes that cleave off the ester from the Testosterone molecule is the reason for the slow release and increased half-life.
Ultimately, Drostanolone Propionate has a half-life of 2.5 days and Drostanolone Enanthate is 10 days. Esterification does not affect the action and characteristics of the hormone in any way, with the exception of increasing the release rate and half-life of the hormone.
Since Masteron is a derivative of DHT, it retains some of the characteristics of the parent hormone. In particular, it does not interact with aromatase. The aromatase enzyme is responsible for the conversion of androgens to estrogens, and Masteron is not affected by this process. Thus, at any dosage, Masteron will not exhibit any estrogenic characteristics. This relieves the drug of the risk of the following side effects: water retention, high blood pressure (due to water retention), potential increase/retention of adipose tissue and gynecomastia. Those who use Masteron only gain muscle mass without water and without the effect of a swollen soft body. That’s why Masteron is preferred by most bodybuilders and athletes as an effective weight loss product, as well as a pre-competition cutting cycle.
Due to its moderate anabolic power, Masteron is not considered an effective tool for gaining mass and volume. Many experienced anabolic steroid users believe that the high price and relatively low anabolic power make the drug useful only among competitive bodybuilders who need to achieve a firm and chiseled appearance for a single stage performance. It has been confirmed that in combination with other individual preparations, Masteron “tears” the body even more. But similar “sealing” properties of Masteron appear in athletes (sportswomen) with a low percentage of adipose tissue in the body. Otherwise, this effect simply will not be noticeable. All this leads to the next, main property of Masteron.
Masteron acts as a mild aromatase inhibitor. It is also able to block estrogen at receptor sites in breast tissue. Thanks to this feature, the drug has become an advanced drug for the treatment of breast cancer. On a lean body (with no more than 10% body fat), Masteron shows a “firming” and “sculpting” effect, as many experienced users say. Masteron works to inhibit the aromatase enzyme, thereby eliminating the ability of estrogen to form from aromatizable anabolic steroids during the aromatization process. In fact, it reduces water retention, as estrogen levels continue to decline due to the increase in inactive aromatase enzymes.
The bodybuilding community regards Masteron as one of the “lightweight” anabolic steroids. This also applies to side effects. Being derived from DHT, it has similar (or similar) attributes and functions. The inability to interact with the aromatase enzyme completely eliminates any side effects associated with estrogen.
As mentioned earlier, Masteron, as a derivative of DHT, is completely devoid of any estrogenic side effects. Not only is it not susceptible to aromatization (conversion to estrogens), but it is also reported to behave as a mild aromatase inhibitor. Side effects resulting from the accumulation of estrogen, such as edema, retention and growth of adipose tissue, the development of gynecomastia, are completely eliminated or reduced when using Masteron.
Although Masteron has a lower androgenic strength than Testosterone, it can still show androgenic side effects. It should be used with caution by those who are predisposed to such effects. An increase in oily skin (as a result of an increase in the production / secretion of sebum), an increase in hair growth on the face and body, the risk of developing androgenetic alopecia (male pattern baldness), virilization (the development of male characteristics) in women are the main side effects of the drug. Masteron has an even stronger negative effect, in comparison with similar compounds, on the level of cholesterol in the blood and on the cardiovascular system in general. This effect is a consequence of Masteron’s antiestrogenic ability – a decrease in serum estrogen levels leads to a symmetrical decrease in HDL levels (high density lipoproteins or “good cholesterol”) and a simultaneous increase in LDL levels (low density lipoproteins or “bad cholesterol”).
Masteron does not show hepatotoxicity (a negative effect on the liver), but, like any anabolic steroid, it helps to suppress / disable HPTA (testosterone hormone production function), thereby reducing endogenous testosterone production.
Courses and application
Masteron courses, as a rule, are very limited in their functionality and dynamics. The drug is not intended for a sharp increase in volume, strength growth, etc. For drying and fat burning, there are much more effective anabolic steroids. The only area of application of Masteron is a course aimed at losing fat mass for bodybuilders in preparation for competitions. But, as a rule, even in courses aimed at reducing the volume of adipose tissue, Masteron does not play a key role.
The short-term effect of Masteron requires long-term use, usually the course is from 8 to 10 weeks. Some bodybuilders choose to use Masteron only during the last 2-4 weeks of the cycle, before a competition or photo session, solely for the purpose of improving the visual physiological characteristics of the body. A typical course begins with a 10-week intake of compounds such as Testosterone Propionate, Trenbolone Acetate and Anavar. By the 6th or 8th week of such a cycle, Masteron is introduced into the course (sometimes removing some other drug) and then taken until the end of the 10th week.
The classic Masteron regimen is aimed at reducing fat mass. It includes an 8-10 week course in parallel with compounds of similar origin such as injectable Winstrol, Testosterone Propionate and sometimes Trenbolone Acetate or Winstrol oral.